Man Group plc Sells 27,033 Shares of Insulet Corporation $PODD

Man Group plc cut its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 434,568 shares of the medical instruments supplier’s stock after selling 27,033 shares during the period. Man Group plc’s holdings in Insulet were worth $123,522,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in Insulet by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after acquiring an additional 87,845 shares during the last quarter. State Street Corp lifted its holdings in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after buying an additional 41,019 shares in the last quarter. Norges Bank acquired a new position in Insulet during the 4th quarter worth $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Insulet by 3.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock worth $229,131,000 after buying an additional 29,690 shares in the last quarter.

Insulet Stock Performance

PODD stock opened at $143.52 on Thursday. The business’s fifty day moving average is $166.47 and its 200-day moving average is $228.11. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a market cap of $9.94 billion, a P/E ratio of 33.38, a price-to-earnings-growth ratio of 1.16 and a beta of 1.13. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays reduced their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. JPMorgan Chase & Co. reduced their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Bank of America reduced their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $240.78.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.36% of the stock is currently owned by company insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.